High-flying biotech Intercept Pharmaceuticals (ICPT) enjoyed a 516% gain last week, but shares have tumbled this week. After yesterday's 18% dive, shares dropped another 30% today. In the following video, analyst Max Macaluso discusses what caused today's drop and the key issues that long-term investors need to focus on.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Biotech Boomer Intercept Pharmaceuticals, Inc. Tumbled Again
NASDAQ: ICPT
Intercept Pharmaceuticals

Why did Intercept shares tumble today?
Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson and also owns shares of Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.